MiniMed Group, Inc. (NASDAQ:MMEDV)
| Market Cap | 495.60M-5.3% |
| Revenue (ttm) | n/a |
| Net Income | n/a-50.0% |
| EPS | n/a |
| Shares Out | 28.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 226,896 |
| Open | 18.20 |
| Previous Close | 17.70 |
| Day's Range | 17.70 - 18.20 |
| 52-Week Range | 15.50 - 21.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 16, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About MMEDV
MiniMed Group, Inc. is a medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its products include insulin delivery devices like pumps and pens, continuous glucose monitors, and related software and services. The company serves people with diabetes who require insulin therapy across more than 80 countries.
$MMEDV stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MMEDV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MMEDV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MMEDV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MMEDV Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| CGM | $431.00M | 51.13% |
| Consumables | $261.00M | 30.96% |
| Pumps | $144.00M | 17.08% |
| Other | $7.00M | 0.83% |
As of: Q3 2026 (Jul 31, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MMEDV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MMEDV from public contracts
Source: USAspending.gov
MMEDV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MMEDV’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.